User:Mr. Ibrahem/Pegfilgrastim

Pegfilgrastim, sold under the brand name Neulasta among others, is a medication used treat low neutrophils in those on chemotherapy or with radiation sickness. Its benefits are similar to filgrastim but does not need to be given as often. It is given by injection under the skin.

Common side effects include bone pain. Other side effects may include splenic rupture, adult respiratory distress syndrome (ADRS), and anaphylaxis. It is a PEGylated form of filgrastim, a recombinant granulocyte colony-stimulating factor (GCSF). It increases the production of white blood cells (leucocytes) by the bone marrow.

Pegfilgrastim was approved for medical use in the United States, Europe, and Australia in 2002. It is on the World Health Organization's List of Essential Medicines. In the United States it costs about 6,200 USD per dose as of 2021; though a biosimilar is available at 3,800 USD per dose. In the United Kingdom this amount costs the NHS about £410.